United States DNA Sequencing Market 2031 | Growth Drivers, Key Players & Investment Opportunities | Leading Companies - Bio-Rad Laboratories Inc., Danaher Corporation, Eurofins Scientific, F. Hoffmann-La Roche, Illumina Inc.

Market Size and Growth

DNA Sequencing Market is expected to grow at a CAGR 11.3% during the forecast period (2024-2031).

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/dna-sequencing-market?sb

Key Development:

United States: Recent Industry Developments

✅ In December 2025, Illumina announced a strategic collaboration and investment in MyOme to advance whole‐genome sequencing (WGS) combined with AI‐integrated risk models for early disease detection and prevention, supporting a large‐scale clinical trial launching in 2026. This partnership aims to expand clinical genomics applications and enhance personalized medicine through next‐generation sequencing and bioinformatics integration.

✅ In November 2025, Pacific Biosciences (PacBio) unveiled updates to its Revio sequencing system with new SPRQ chemistry, increasing throughput and lowering genome sequencing costs, while also launching the VegaTM benchtop sequencer to bring high‐accuracy long‐read capabilities to more laboratories. These advances expand access to highly accurate DNA sequencing across research and clinical settings in the U.S. market.

✅ In June 2025, Illumina entered a definitive agreement to acquire SomaLogic for $350 million plus up to $75 million in milestones, strengthening its multi‐omics and sequencing platform capabilities across proteomics and genomics workflows. This strategic acquisition expands Illumina's DNA sequencing ecosystem and accelerates innovation in high‐throughput genetic and proteomic analysis.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=dna-sequencing-market

Japan: Recent Industry Developments

✅ In October 2025, MGI Tech and Genesis Healthcare signed a Memorandum of Understanding (MoU) to collaborate on advancing precision health, multi‐omics, and DNA sequencing applications in Japan, leveraging MGI's DNBSEQTM sequencing technology and local clinical expertise. The partnership aims to broaden the adoption of advanced genomic technologies in research, diagnostics, and clinical settings across Japan.

✅ In October 2025, SOPHiA GENETICS and A.D.A.M. Innovations (formerly Genesis Healthcare) announced a strategic partnership in Japan to bring AI‐powered liquid biopsy genomic testing and companion diagnostic solutions to the Japanese market. This collaboration focuses on accelerating personalized cancer care by expanding access to cutting‐edge genomic profiling through liquid biopsy platforms.

✅ In October 2025, MGI Tech and Genesis Healthcare signed a Memorandum of Understanding to collaborate on precision health, multi‐omics, and DNA sequencing applications, leveraging MGI's DNBSEQ technology for clinical and research initiatives. The MoU accelerates adoption of next‐generation sequencing in Japan's genomics and healthcare sectors

Key Players:

=> Agilent Technologies Inc., Bio-Rad Laboratories Inc., Danaher Corporation, Eurofins Scientific, F. Hoffmann-La Roche, Illumina Inc., Merck KGaA, Pacific Biosciences of California Inc., PerkinElmer Inc., and Thermo Fisher Scientific Inc.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/dna-sequencing-market?sb

Key Segments:

By Product Type

Instruments lead with 45% share, driven by increasing adoption of advanced sequencing platforms, automation, and high-throughput capabilities in clinical and research settings. Consumables account for 40%, supported by recurring demand for reagents, kits, flow cells, and sample preparation materials required for sequencing workflows. Other products hold 15%, including software tools, accessories, and ancillary laboratory equipment supporting sequencing operations.

By Sequencing Type

Next-Generation Sequencing (NGS) dominates with 65% share, fueled by its high accuracy, scalability, cost-effectiveness, and widespread use in diagnostics and personalized medicine. Sanger Sequencing accounts for 25%, supported by its reliability, validation applications, and targeted sequencing needs. Other sequencing technologies hold 10%, including emerging and niche platforms used for specialized research applications.

By Application

Diagnostics lead with 50% share, driven by increasing use of sequencing in oncology, infectious disease testing, and genetic disorder diagnosis. Personalized Medicine accounts for 35%, supported by growing adoption of genomics-based treatment decisions, pharmacogenomics, and precision healthcare. Other applications hold 15%, including academic research, drug discovery, and population genomics studies.

By Region

North America - 38% Share
North America leads with 38%, driven by advanced healthcare infrastructure, strong genomics research funding, and widespread adoption of sequencing technologies in the U.S. and Canada.

Europe - 28% Share
Europe holds 28%, supported by national genomics initiatives, strong diagnostic adoption, and research activities across Germany, France, the U.K., Italy, Spain, and neighboring countries.

Asia Pacific - 25% Share
Asia Pacific accounts for 25%, fueled by expanding healthcare infrastructure, rising genomic research investments, and growing diagnostics adoption in China, India, Japan, and Southeast Asia.

Middle East & Africa - 5% Share
The Middle East & Africa represent 5%, supported by emerging genomics programs, healthcare modernization, and increasing research collaborations in GCC countries and South Africa.

Latin America - 4% Share
Latin America holds 4%, driven by growing diagnostics adoption, research initiatives, and improving access to sequencing technologies in Brazil, Mexico, and surrounding regions.

FAQ

Q: What is the growth rate of the DNA Sequencing Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 11.3% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.